[go: up one dir, main page]

WO2015073709A3 - Detection of atherosclerotic cardiovascular disease risk - Google Patents

Detection of atherosclerotic cardiovascular disease risk Download PDF

Info

Publication number
WO2015073709A3
WO2015073709A3 PCT/US2014/065524 US2014065524W WO2015073709A3 WO 2015073709 A3 WO2015073709 A3 WO 2015073709A3 US 2014065524 W US2014065524 W US 2014065524W WO 2015073709 A3 WO2015073709 A3 WO 2015073709A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disease
detection
atherosclerotic cardiovascular
disease risk
ascvd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/065524
Other languages
French (fr)
Other versions
WO2015073709A2 (en
Inventor
Daniel Levy
Ralph B. D'AGOSTINO
Jennifer E. HO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
US Department of Health and Human Services
Original Assignee
Boston University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, US Department of Health and Human Services filed Critical Boston University
Publication of WO2015073709A2 publication Critical patent/WO2015073709A2/en
Publication of WO2015073709A3 publication Critical patent/WO2015073709A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods are disclosed herein for determining the likelihood that a subject will develop atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF). Methods are also disclosed for determining if a pharmaceutical agent is effective for the treatment or prevention of ASCVD or HF.
PCT/US2014/065524 2013-11-14 2014-11-13 Detection of atherosclerotic cardiovascular disease risk and heart failure risk Ceased WO2015073709A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904410P 2013-11-14 2013-11-14
US61/904,410 2013-11-14

Publications (2)

Publication Number Publication Date
WO2015073709A2 WO2015073709A2 (en) 2015-05-21
WO2015073709A3 true WO2015073709A3 (en) 2015-08-27

Family

ID=52144850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/065524 Ceased WO2015073709A2 (en) 2013-11-14 2014-11-13 Detection of atherosclerotic cardiovascular disease risk and heart failure risk

Country Status (1)

Country Link
WO (1) WO2015073709A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
KR20230057410A (en) 2020-08-25 2023-04-28 리제너론 파마슈티칼스 인코포레이티드 Treatment of sepsis using PCSK9 and LDLR modulators
CN112194724B (en) * 2020-10-19 2022-01-14 福州迈新生物技术开发有限公司 anti-MPO protein monoclonal antibody, cell line, preparation method and application thereof
EP4356142A4 (en) * 2021-06-16 2025-07-23 Endothelium Scanning Nanotechnology Ltd BIOMARKERS AND DRUG COMBINATIONS TO PREDICT HEART FAILURE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232385A1 (en) * 2002-06-17 2003-12-18 Breit Samuel N. Methods of diagnoisis, prognosis and treatment of cardiovascular disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2548112B2 (en) 1983-09-02 1996-10-30 シンジェン，インコーポレイテッド Carrier and oligonucleotide synthesis
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
PT700521E (en) 1993-05-28 2003-10-31 Baylor College Medicine METHOD AND MASS SPECTROMETER FOR DESSORING AND IONIZATION OF ANALYZES
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
AU2360195A (en) 1994-05-05 1995-11-29 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
KR100713786B1 (en) 1999-04-27 2007-05-07 바이오 래드 래버러토리스 인코오포레이티드 Probe for Gas Phase Ion Spectrometer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232385A1 (en) * 2002-06-17 2003-12-18 Breit Samuel N. Methods of diagnoisis, prognosis and treatment of cardiovascular disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
G. A. BONATERRA ET AL: "Growth Differentiation Factor-15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin-6-Dependent Inflammatory Response to Vascular Injury", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 1, no. 6, 13 December 2012 (2012-12-13), pages e002550 - e002550, XP055167960, DOI: 10.1161/JAHA.112.002550 *
KAI M. EGGERS: "Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects, Scandinavian Journal of Clinical & Laboratory Investigation, Informa Healthcare", 1 February 2012 (2012-02-01), XP055168093, Retrieved from the Internet <URL:http://informahealthcare.com/doi/abs/10.3109/00365513.2011.626072> [retrieved on 20150206] *
KATHLEEN M. EYSTER ET AL: "Gene expression signatures differ with extent of atherosclerosis in monkey iliac artery", MENOPAUSE, vol. 18, no. 10, 1 October 2011 (2011-10-01), pages 1087 - 1095, XP055167966, ISSN: 1072-3714, DOI: 10.1097/gme.0b013e3182163fea *
LEVY DANIEL ET AL: "Protein Biomarkers of New-Onset Atherosclerotic Cardiovascular Disease", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 128, no. 22, suppl, 18 November 2013 (2013-11-18), pages 15535, XP009182154, ISSN: 0009-7322 *
V. XANTHAKIS ET AL: "Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 2, no. 6, 7 November 2013 (2013-11-07), pages e000399 - e000399, XP055164537, DOI: 10.1161/JAHA.113.000399 *
XIAOYAN YIN: "Protein Biomarkers of New-Onset Cardiovascular Disease", ARTERIOSCLER THROMB VASC BIOL, 1 April 2014 (2014-04-01), pages 939 - 945, XP055164209, Retrieved from the Internet <URL:http://atvb.ahajournals.org/content/34/4/939.full.pdf> [retrieved on 20150122] *

Also Published As

Publication number Publication date
WO2015073709A2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
WO2015073710A3 (en) Detection of atherosclerotic cardiovascular disease risk
ZA201705032B (en) Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
WO2012054589A3 (en) Conduit-containing devices and methods for analyte processing and detection
HK1211475A1 (en) Combination therapy
GB2555628B (en) Main processor error detection using checker processors
EP3644220A4 (en) ELECTROCARDIOGRAM SIGNAL DETECTION
EP3166482A4 (en) System and method for distinguishing a cardiac event from noise in an electrocardiogram (ecg) signal
EP3337782A4 (en) DIACEREIN OR ITS ANALOGUES FOR INHIBITING THE EXPRESSION OF ASC AND NLRP3 PROTEINS, AND / OR THE FORMATION OF THE INFLAMMASOME COMPLEX NLRP3
HUE045724T2 (en) GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer
WO2012075126A3 (en) Methods and apparatus related to photothermal optical coherence tomography (oct)
EP3200697A4 (en) Infrasonic stethoscope for monitoring physiological processes
DK3189653T3 (en) CONTACT CENTER-ANTI-FRAUD-MONITORING, DETECTION AND PREVENTION SOLUTION
EP3249362A4 (en) Insole with integrated nano-pedometer, step detection and counting method using said insole, and shoe equipped with the fixed or removable insole
WO2014197816A8 (en) Stimulus responsive nanocomplexes and methods of use thereof
WO2016043947A3 (en) Spectral signature drug detection
FR3030284B1 (en) SAFETY LOCKING SYSTEM, CARABINER USABLE FOR SUCH A SYSTEM AND ARRIMAGE ASSEMBLY COMPRISING SUCH A SYSTEM
WO2015073709A3 (en) Detection of atherosclerotic cardiovascular disease risk
PL3636774T3 (en) Method for the detection of C. perfringens diseases in animals
JP2014054318A5 (en)
HK1244881A1 (en) Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disase
EP3288452A4 (en) Noninvasive system and methods for utilizing impedance for the detection of cerebrospinal fluid volume
EP3706625A4 (en) Reducing false alarms in patient monitoring
EP2741660A4 (en) Devices, systems and methods for the detection of coronary artery disease
HUE042012T2 (en) Non-invasive procedure for the detection of pre-natal fetal chromosome aneuploidia from maternal blood
IT1402105B1 (en) WEARABLE DEVICE FOR DIAGNOSIS OF CARDIAC AND / OR PATHOLOGIES FOR THE DETECTION OF HEMODYNAMIC VARIABLES.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14816478

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14816478

Country of ref document: EP

Kind code of ref document: A2